A retrospective study to assess safety measures of durvalumab therapy (two and four-weekly adjuvant treatemtn) in patients with stage III NSCLC in response to COVID-19 pandemic
Latest Information Update: 07 Jul 2021
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- 07 Jul 2021 New trial record
- 01 Jun 2021 Results published in the Lung Cancer